Outpatient convalescent plasma therapy for high-risk patients with early COVID-19. A randomized placebo-controlled trial.

Gharbharan, ArvindJordans, CarlijnZwaginga, LisaPapageorgiou, Grigoriosvan Geloven, Nanvan Wijngaarden, Peterden Hollander, JanKarim, Faizvan Leeuwen-Segarceanu, ElenaSoetekouw, RobertLammers, JolandaPostma, DouweKampschreur, LindaGroeneveld, GeertSwaneveld, FrancisEllen van der Schoot, CGötz, HanneloreHaagmans, BartKoopmans, MarionBogers, SusanneGeurtsvankessel, CorineZwaginga, Jaap JanRokx, CasperRijnders, Bart2022-08-302022-08-302022-08-223600787010.1016/j.cmi.2022.08.005http://hdl.handle.net/10029/626049enCopyright © 2022. Published by Elsevier Ltd.AntibodiesCOVID-19Convalescent plasmaOutpatientsOutpatient convalescent plasma therapy for high-risk patients with early COVID-19. A randomized placebo-controlled trial.Article1469-0691Clinical microbiology and infection 2023 ;29(2):208-214